Cardiac Power Output in Cardiogenic Shock Patients
Recruiting · NCT05700617 · Interventional (participants receive a specific treatment) · Lead sponsor: University of Chicago
View the official record on ClinicalTrials.gov →Interventions studied
1:1 Randomization to receive milrinone
What this trial is about
The main purpose of this study is to determine whether differences in myocardial reserve predict clinical outcomes for heart failure patients.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Early Phase 1
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- LVEF ≤ 40%
- Referred for RHC for:
- Evaluation for advanced heart failure therapies, including LVAD, OHT, temporary or long-term inotrope therapy, or counter-pulsation (temporary or long-term with NuPulse device OR
- Accurate assessment of invasive hemodynamics due to worsening clinical status, OR
- Assessment of myocardial recovery for consideration of LVAD or counter-pulsation (temporary IABP or long-term with NuPulse device) decommissioning or removal OR
- Assessment of cardiac function and valvular abnormalities prior to planned valvular surgery for MR or AI
- Estimated glomerular filtration rate (eGFR) ≥ 30 ml/min/1.73 m2
- Age ≥ 18 years-old
- Intent for admission based on RHC data
Exclusion criteria
- eGFR \< 30 ml/min/1.73 m2
- Severe, non-revascularized coronary artery disease
- Concurrent acute coronary syndrome
- Age \< 18 years-old
- History of significant ventricular arrhythmia without an ICD
Where it is running
1 location listed across 1 US state.
- The University of Chicago - Chicago, Illinois, United States